Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by Stylesson Mar 26, 2015 12:51pm

71 Views

Post# 23564798

RE:share price

Here's the issue though.

Even at this much lower price the stock trades at 18x next twelve months p/e and 10.5 ev/ebitda.

That's not cheap for a company with below peer group growth.

The issue was the stock was expensive at 19. now it's just re-rating to a valuation that better reflects the business.

nothing is wrong with the company. just going from overvalued to fairly valued.

If they do an accretive transaction that materially improves the business and earnings/cash flow, stock should go higher. Like every other acquisition healthcare company (NHC, CRH, GUD, CXR, etc.)

Bullboard Posts

Global Tungsten Market and Supply Security